Gilead (GILD) volatility elevated into less than expected Q1 results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Gilead Sciences (GILD) PT Lowered to $90 at RBC Capital
May 2, 2018 8:26 AM EDTRBC Capital lowered its price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $94.00) while maintaining an Outperform rating following a disappointing quarter.
... More
Gilead Sciences (GILD) PT Lowered to $79 at Baird
May 2, 2018 7:51 AM EDTBaird lowered its price target on Gilead Sciences (NASDAQ: GILD) to $79.00 (from $87.00) while maintaining an Outperform rating on weaker than expected 1Q.
Analyst Brian Skorney commented, "While investors had projected 2018 as a trough earnings year for the company, worse than expected sales... More
Gilead Sciences (GILD) PT Lowered to $81 at Morgan Stanley
May 2, 2018 7:45 AM EDTMorgan Stanley lowered its price target on Gilead Sciences (NASDAQ: GILD) to $81.00 (from $85.00) while maintaining a Equalweight rating following the company's 1Q earnings report.
1Q18 EPS missed by $0.17. The miss was driven by lower than expected total revenues ($5.1B vs. $5.4B... More
